PT  - JOURNAL ARTICLE
AU  - Upasani, Vinit
AU  - O’Sullivan, Mary
AU  - Moreira, Fernando
AU  - Workman, Sarita
AU  - Symes, Andrew
AU  - Burns, Siobhan O
AU  - Tadros, Susan
AU  - McCoy, Laura
AU  - Lowe, David M
TI  - Commercial immunoglobulin products now contain neutralising antibodies against SARS-CoV-2 spike protein which are detectable in patient serum
AID  - 10.1101/2022.09.22.22280216
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.22.22280216
4099  - http://medrxiv.org/content/early/2022/09/26/2022.09.22.22280216.short
4100  - http://medrxiv.org/content/early/2022/09/26/2022.09.22.22280216.full
AB  - Antibody-deficient patients respond poorly to COVID-19 vaccination and are at risk of severe or prolonged infection. Prophylaxis with anti-SARS-CoV-2 monoclonal antibodies has been considered. We here demonstrate that many immunoglobulin preparations now contain neutralising anti-SARS-CoV-2 antibodies which are transmitted to patients in good concentrations, albeit with significant differences between products.Competing Interest StatementS.W. has received personal fees from UCB and LFB Biopharmaceuticals and sponsorship to attend meetings from Biotest, CSL Behring and Octapharma. A.S. has received personal fees for a webinar from CSL Behring. S.O.B. has received grant support from CSL Behring, personal fees or travel expenses from Immunodeficiency Canada/IAACI, CSL Behring, Baxalta US Inc and Biotest and fees as an external expert for GSK. D.M.L has received personal fees from Gilead for an educational video on COVID-19 in immunodeficiency, from Merck for a roundtable discussion on risk of COVID-19 in immunosuppressed patients and speaker fees from Biotest. D.M.L. also holds research grants from GSK and Bristol Myers Squibb, outside the current work. All other authors declare no conflicts of interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All donors provided written informed consent under protocols approved by a UK National Health Service (NHS) research ethics committee (Hampstead Research Ethics Committee, Refs 04/Q0501/119 and 08/H0720/46).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.